Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bonn

About this trial

The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR). This longitudinal study aims to dissect the complex immunological landscape and systemic manifestations of these conditions through a combination of diagnostic imaging and detailed immunological profiling.

The study focuses on three primary objectives: (1) Identifying and analyzing cytokine profiles and immune cell phenotypes, employing techniques like flow cytometry, enzyme-linked immunosorbent assays (ELISA), and next-generation sequencing to predict disease activity and therapeutic responses. (2) Advancing diagnostic and monitoring capabilities through the application of novel and established imaging technologies, including MRI, optical coherence tomography angiography (OCTA), and ultrasound. These modalities aim to improve the detection of neuro-ophthalmological, cardiac, and aortic complications in GCA, potentially offering more precise monitoring and earlier diagnosis. (3) Enhancing the understanding of PMR within the context of GCA by exploring specific biomarkers and advanced imaging to refine diagnostic accuracy and treatment strategies, thus improving patient outcomes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Informed Consent: Participants (>18 years) must provide written informed consent to voluntarily participate in the study.

Confirmed Diagnosis: Diagnosis of GCA or PMR confirmed by the treating physician and fulfilling expanded ACR-EULAR classification criteria. Patients must have been either newly diagnosed within the last three days or have experienced a disease flare within the same timeframe.

Disqualifiers

Severe Renal Insufficiency: Chronic glomerular filtration rate (GFR) less than 30 mL/min.

Other Medical Conditions Requiring Glucocorticoids: Presence of medical conditions other than GCA or PMR that necessitate continuous or intermittent treatment with oral or parenteral glucocorticoids.

Other Inflammatory Rheumatic Diseases: Patients with other inflammatory rheumatic diseases.

Trial population

The GCAIO study focuses on patients with newly diagnosed GCA and PMR or those experiencing a flare-up. The primary sites for patient recruitment include the ophthalmological and rheumatological departments of the University Hospital of Bonn, Germany. Additional participants can be referred by local rheumatologists and primary care physicians. Healthy controls are recruited through the ophthalmological and rheumatological department of the University Hospital Bonn.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • Aortic/ cardiac magnetic resonance imaging

    Diagnostic test

    MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.

  • Vascular ultrasound

    Diagnostic test

    Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.

  • Transorbital Ultrasound

    Diagnostic test

    Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.

  • Contrast-Enhanced Ultrasound

    Diagnostic test

    Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.

  • Optical coherence tomography angiography

    Diagnostic test

    OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.

  • Fluorescein angiography

    Diagnostic test

    Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.

  • Fundus autofluorescence

    Diagnostic test

    This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.

  • Color Fundus Photography

    Diagnostic test

    Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.

  • Cell-based ex-vivo assay with high-content analysis

    Diagnostic test

    This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.

  • 3'mRNA sequencing

    Diagnostic test

    3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.

  • Enzyme-linked immunosorbent assay

    Diagnostic test

    Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.

  • Flow cytometry

    Diagnostic test

    Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.

  • Laboratory assessment:

    Diagnostic test

    Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)

  • Immunohistochemistry of Temporal Artery Biopsies

    Diagnostic test

    Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.

  • Functional assessment questionnaires

    Diagnostic test

    The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: PMR/ GCA15 interventions
Group B: Control Group14 interventions

Trial outcomes

Primary outcomes

1

Number of Participants with Detected Neuro-Ophthalmological Manifestations

Use of OCTA, TOS, and additional ocular imaging to assess and monitor ocular and cranial vascular abnormalities indicative of GCA. Unit of Measure: Number of participants.

Time frame
At baseline, 3 months, 6 months, 9 months, 12 months, 18 months, and during flare-ups (assessed up to 18 months after diagnosis).
2

Number of Participants with Detected Cardiac and Aortic Involvement

Detection and monitoring of inflammatory changes and structural anomalies in the cardiac and aortic regions using MRI and CEUS. Unit of Measure: Number of participants.

Time frame
At baseline, 6 months, 12 months, 18 months, and during flare-ups (assessed up to 18 months after diagnosis).
3

Changes in Immune Cell Phenotype

Identification and quantification of immune cell types including changes over time using FACS. Unit of Measure: Changes in levels (percentages).

Time frame
At baseline, 6 months, 12 months, 18 months, and during flare-ups (assessed up to 18 months after diagnosis).
4

Changes in Cytokine Profiles

Identification and quantification of cytokines including changes over time using 3'-mRNA transcriptome analysis. Unit of Measure: Changes in levels (pg/mL).

Time frame
At baseline, 6 months, 12 months, 18 months, and during flare-ups (assessed up to 18 months after diagnosis).

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Bonn

Lead sponsor

University Hospital, Bonn

Sponsor institution